Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMA validates Bayer’s asundexian application for ischaemic stroke
The study compared asundexian 50mg plus antiplatelet therapy to placebo in post-ischaemic stroke or high-risk TIA patients. Credit: Jo Panuwat D / Shutterstock.com.
The study compared asundexian 50mg plus antiplatelet therapy to placebo in post-ischaemic stroke or high-risk TIA patients. Credit: Jo Panuwat D / Shutterstock.com.